Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Development of Smart Food /Nutraceutical Solutions Dedicated to Cardiometabolic Disorders in Ageing (NutriAge)

11. September 2026 aktualisiert von: Flavia Prodam, Azienda Ospedaliero Universitaria Maggiore della Carita

NUTRI.AGE: DEVELOPMENT OF SMART FOOD/NUTRACEUTICAL SOLUTIONS DEDICATED TO CARDIOMETABOLIC DISORDERS IN AGEING

Describe the anthropometric measurements and informations relating to body composition, blood chemistry tests, blood glucose monitoring, and dietary habits of the volunteers participating in the study before and after taking probiotics.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The clinical research is aimed at exploring the in vivo functionality in humans of ingredients produced and formulated at a pre-competitive pilot level, namely the ability to reduce blood pressure or modify the RAAS (renin-angiotensin-aldosterone system) through the presence of substrates with ACE-inhibitory activity, and/or improve metabolic status through the administration of probiotic strains whose products have a known metabolic effect in in vitro, in vivo animal, or human models (in other subject categories). The use of "enhanced bioactive compounds" (ACE inhibitors, pre-, pro-, and post-biotics) together with selected probiotics in newly formulated food supplements may be strategic in supporting specific diets and pharmacological treatments in older adults with cardiometabolic disorders (CVD). The result of these technological convergences will culminate with the in vivo trial of some nutraceutical-food systems useful for the well-being of the elderly suffering from cardiometabolic pathologies (CVDs).

Studientyp

Interventionell

Einschreibung (Geschätzt)

15

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Novara, Italien, 28100
        • Rekrutierung
        • SCDU Endocrinology. AOU Ospedale Maggiore della Carità
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Patients of either gender, over 65 years of age, able to understand the protocol procedures.
  • Known cardiovascular disease
  • Prediabetes or type 2 diabetes mellitus with HbA1c < 7.0% on diet alone or metformin.

Exclusion Criteria:

  • Age under 65
  • Previous diagnosis of type 2 diabetes mellitus already undergoing drug therapy (except metformin)
  • Contraindications such as allergy to product components
  • Obesity secondary to diseases: genetic (Prader-Willi syndrome, Down syndrome); metabolic and endocrine (Cushing's syndrome, hypothyroidism)
  • Endocrine or liver disease or clinical evidence of chronic disease or gastrointestinal disorders or malabsorption disorders
  • History of adrenal adenoma or secondary arterial hypertension due to renal/adrenal causes
  • Arterial hypertension treated with an ACE inhibitor or ARB
  • Previous bariatric surgery

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Placebo
Participants will receive a placebo for 60 days to allow comparison of the results with those observed in the intervention arm. Participants will take one placebo capsule once daily in the morning, on an empty stomach.
Participants will receive a probiotic for 60 days to allow comparison of the results with those observed in the placebo arm. Participants will take one probiotic capsule once daily in the morning, on an empty stomach.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Blood glucose assessment with OGTT test and FGM
Zeitfenster: 4 months
Blood glucose and insulin tests at 0', 30', 60', 90', 120' minutes every 30 minutes Blood glucose monitoring at home
4 months
Pressure assessment
Zeitfenster: 4 months
Blood pressure is assessed during the visit at time 0 and after 60 days Filling out a blood pressure diary at home
4 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Anthropometric measurements
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
Weight is assessed in Kg with the use of the bioimpedance balance.
evaluation of weight and body composition through study completion, an average of 4 months
Anthropometric measurements
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
the height is measured in cm through a wall altimeter
evaluation of weight and body composition through study completion, an average of 4 months
Anthropometric measurements
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
the BMI (body mass index) is calculated by making the ratio of the weight to the square of the height. normal weight is defined as 18.5-24.9 kg/m², overweight as 25.0-29.9 kg/m², and obesity as ≥30.0 kg/m
evaluation of weight and body composition through study completion, an average of 4 months
Anthropometric measurements
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
Waist, hip, arm, and calf circumferences are measured using an inelastic measuring tape. Waist circumference is also assessed as an indicator of abdominal obesity and increased cardiometabolic risk, using the following reference cut-off values for European populations: ≥94 cm in men and ≥80 cm in women.
evaluation of weight and body composition through study completion, an average of 4 months
Adherence level to the Western diet with European Prospective Investigation into Cancer and Nutrition (EPIC) questionnaires
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
Assessed with the use of questionnaire. EPIC is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition. This is a qualitative questionnaires and not quantitative.
evaluation of weight and body composition through study completion, an average of 4 months
Adherence level to the Western diet with 24h recall questionnaires
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
Assessed with the use of questionnaires. 24h recall questionnaire is used for the bromatology evaluation of the diet, so there aren't scales but only indication about the macro and micronutrient composition. This is a qualitative questionnaires and not quantitative.
evaluation of weight and body composition through study completion, an average of 4 months
Advanced glycation end products quantification
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
AGE levels will be measured using skin fluorescence, using the "AGE reader mu" device (range from 1.3 to 5 level of AGEs respect to the patient's age)
evaluation of weight and body composition through study completion, an average of 4 months
Endogenous and exogenous AGEs plasma quantification
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
AGEs will also be assessed at the plasma level in free form (ELISA, fluorescence assay) or bound to hemoglobin (HbA1c clinical practice test), both measured in pg/mL
evaluation of weight and body composition through study completion, an average of 4 months
Soluble RAGEs plasma quantification
Zeitfenster: evaluation of weight and body composition through study completion, an average of 4 months
RAGEs will also be assessed at the plasma level in solule form (ELISA) measured in pg/mL
evaluation of weight and body composition through study completion, an average of 4 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Flavia Prodam, MD PhD, AOU Maggiore della Carita

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

  • [1] Vadim N. GladyshevAging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes,06 April 2016 https://doi.org/10.1111/acel.12480. [2] Guo, J., Huang, X., Dou, L. et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Sig Transduct Target Ther 7, 391 (2022). https://doi.org/10.1038/s41392-022-01251-0. [3] http://dati-anziani.istat.it/Index.aspx [4] https://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?id=3074 [5] Ilse Bloom, Mark Edwards, Karen A. Jameson, Holly E. Syddall, Elaine Dennison, Catharine R. Gale, Janis Baird, Cyrus Cooper, Avan Aihie Sayer, Sian Robinson, Influences on diet quality in older age: the importance of social factors, Age and Ageing, Volume 46, Issue 2, March 2017, Pages 277-283, https://doi.org/10.1093/ageing/afw180 [6] https://doi.org/10.1093/ageing/afw180Ragonnaud, E., Biragyn, A. Gut microbiota as the key controllers of "healthy" aging of elderly people. Immun Ageing 18, 2 (2021). https://doi.org/10.1186/s12979-020-00213-w [7] Nuria Salazar, Lorena Valdés-Varela, Sonia González, Miguel Gueimonde & Clara G. de los Reyes-Gavilán (2017) Nutrition and the gut microbiome in the elderly, Gut Microbes, 8:2, 82- 97, DOI: 10.1080/19490976.2016.1256525 [8] Białecka-Dębek, A.; Granda, D.; Szmidt, M.K.; Zielińska, D. Gut Microbiota, Probiotic Interventions, and Cognitive Function in the Elderly: A Review of Current Knowledge. Nutrients 2021, 13, 2514. https://doi.org/10.3390/nu13082514 [9] Hutchinson, A.N.; Bergh, C.; Kruger, K.; Sűsserová, M.; Allen, J.; Améen, S.; Tingö, L. The Effect of Probiotics on Health Outcomes in the Elderly: A Systematic Review of Randomized, Placebo-Controlled Studies. Microorganisms 2021, 9, 1344. https://doi.org/10.3390/microorganisms9061344 [10] ALE, Elisa C.; BINETTI, Ana G. Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Frontiers in Microbiology, 2021, 12: 631254. [11] Wu, H.; Chiou, J. Potential Benefits of Probiotics and Prebiotics for Coronary Heart Disease and Stroke. Nutrients 2021, 13, 2878. https://doi.org/10.3390/nu13082878 [12] Kiersnowska K, Jakubczyk A. Bioactive Peptides Obtained from Legume Seeds as New Compounds in Metabolic Syndrome Prevention and Diet Therapy. Foods. 2022 Oct 21;11(20):3300. doi: 10.3390/foods11203300. PMID: 37431048; PMCID: PMC9602117. [13] Alexander R, Khaja A, Debiec N, Fazioli A, Torrance M, Razzaque MS. Health-promoting benefits of lentils: Anti-inflammatory and anti-microbial effects. Curr Res Physiol. 2024 Mar 5;7:100124. doi: 10.1016/j.crphys.2024.100124. PMID: 38501131; PMCID: PMC10945126. [14] Rezvankhah A, Yarmand MS, Ghanbarzadeh B, Mirzaee H. Development of lentil peptides with potent antioxidant, antihypertensive, and antidiabetic activities along with umami taste. Food Sci Nutr. 2023 Feb 27;11(6):2974-2989. doi: 10.1002/fsn3.3279. PMID: 37324857; PMCID: PMC10261806. [15] Nicola Faccilongo, Giustina Pellegrini, Piermichele La Sala, Economia circolare e scarti nelle filiere agroalimentari: prima indagine esplorativa sullo stato dell'arte, in

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

24. Juni 2025

Primärer Abschluss (Tatsächlich)

30. September 2025

Studienabschluss (Geschätzt)

30. November 2026

Studienanmeldedaten

Zuerst eingereicht

7. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. September 2026

Zuerst gepostet (Tatsächlich)

14. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

14. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CE070/2025

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .